MedTrace Logo

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

NCT06461533 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-05-22

No results posted yet for this study

Summary

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.

During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Conditions

  • Acquired Hemophilia A

Interventions

DRUG

Susoctocog Alfa (Genetical Recombination)

Susoctocog Alfa (Genetical Recombination), Intravenous injection

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2029-10-31
Completion
2029-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06461533 on ClinicalTrials.gov